1-2 of 2
Tressa D. Randall
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)

Gregory N. Dietsch, Tressa D. Randall, Raphael Gottardo, Donald W. Northfelt, Ramesh K. Ramanathan, Peter A. Cohen, Kristi L. Manjarrez, Mona Newkirk, James Kyle Bryan, Robert M. Hershberg
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5445–5452.
https://doi.org/10.1158/1078-0432.CCR-15-0578
Published: 14 December 2015
View article titled, Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)
Open the PDF for Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337) in another window
Journal Articles

A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma

Donald W. Northfelt, Ramesh K. Ramanathan, Peter A. Cohen, Daniel D. Von Hoff, Glen J. Weiss, Gregory N. Dietsch, Kristi L. Manjarrez, Tressa D. Randall, Robert M. Hershberg
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (14): 3683–3691.
https://doi.org/10.1158/1078-0432.CCR-14-0392
Published: 14 July 2014
View article titled, A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma
Open the PDF for A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma in another window